Please assess the completion status of the following clinical trial:

Trial Title: A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) between 18 and 32 kg/m\^2~* In good health, determined be no clinically significant findings from medical history, physical examination, and screening evaluations~* Female subjects must be of nonchildbearing potential~* Male subjects must agree to use contraception or must be surgically sterile for at least 90 days prior to enrollment~* Able to understand and sign informed consent form~Exclusion Criteria:~* Any condition affecting drug absorption (including stomach or intestinal surgery)~* Significant history of metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder~* History of hypersensitivity, intolerance, or allergy to any drug compounds, food, or other substance (unless approved by Investigator)~* Participation in a clinical study involving an investigational drug within the past 30 days~* Use or intend to any prescription medications within 28 days prior to check in~* Use of tobacco- or nicotine-containing products within 28 days prior to check in~* History of hyperbilirubinemia~* History of alcoholism or drug abuse within 2 years~* History of regular alcohol consumption exceeding 7 drinks/week for female subjects or 14 drinks/week for male subjects~* Positive hepatitis panel and/or positive human immunodeficiency virus (HIV) test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Part A (Type: EXPERIMENTAL): Tucatinib plus Itraconazole
- Part B (Type: EXPERIMENTAL): Tucatinib plus Rifampin
- Part C (Type: EXPERIMENTAL): Tucatinib plus Gemfibrozil
- Part D (Type: EXPERIMENTAL): Tucatinib plus Repaglinide plus Tolbutamide plus Midazolam
- Part E (Type: EXPERIMENTAL): Tucatinib plus Digoxin

Based on this trial design, predict the completion outcome and termination type (if applicable).